嘉应制药：完成回购0.1970%至2.048%公司股份

Core Viewpoint - The company has approved a share repurchase plan, intending to buy back between 7 million and 13.5 million shares using its own funds, with a total expenditure not exceeding 132 million yuan [1] Group 1: Share Repurchase Plan - The board of directors approved the share repurchase plan during the fourth temporary meeting of the seventh board on December 12, 2024 [1] - The repurchase will be conducted through centralized bidding, targeting a minimum of 7 million shares and a maximum of 13.5 million shares [1] - The total amount allocated for the repurchase will not exceed 132 million yuan [1] Group 2: Current Repurchase Status - As of October 9, 2025, the company has repurchased a total of 10.396 million shares, representing 2.048% of the current total share capital [1] - The highest transaction price during the repurchase was 7.04 yuan per share, while the lowest was 5.96 yuan per share [1] - The total amount spent on the repurchase so far is approximately 69.9872 million yuan [1]